Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA HEPARIN MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE MIDDLE EAST AND AFRICA HEPARIN MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 MIDDLE EAST AND AFRICA HEPARIN MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10 PIPELINE ANALYSIS
10.1 CLINICAL TRIALS AND PHASE ANALYSIS
10.2 DRUG THERAPY PIPELINE
10.3 PHASE III CANDIDATES
10.4 PHASE II CANDIDATES
10.5 PHASE I CANDIDATES
10.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR XX
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
11 MARKETED DRUG ANALYSIS
11.1 DRUG
11.1.1 BRAND NAME
11.1.2 GENERICS NAME
11.2 THERAPEUTIC INDICTION
11.3 PHARMACOLOGICAL CLASS OF THE DRUG
11.4 DRUG PRIMARY INDICATION
11.5 MARKET STATUS
11.6 MEDICATION TYPE
11.7 DRUG DOSAGES FORM
11.8 DOSAGES AVAILABILITY
11.9 DRUG ROUTE OF ADMINISTRATION
11.1 DOSING FREQUENCY
11.11 DRUG INSIGHT
11.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
11.12.1 FORECAST MARKET OUTLOOK
11.12.2 CROSS COMPETITION
11.12.3 THERAPEUTIC PORTFOLIO
11.12.4 CURRENT DEVELOPMENT SCENARIO
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 MARKET OVERVIEW
14.1 DRIVERS
14.2 RESTRAINTS
14.3 OPPORTUNITIES
14.4 CHALLENGES
15 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY AVAILABILITY
15.1 OVERVIEW
15.2 RAW
15.3 PROCESSED
16 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY SOURCE
16.1 OVERVIEW
16.2 BIOLOGICAL
16.2.1 BOVINE
16.2.2 PROCINE
16.3 SYNTHETIC
17 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY PRODUCT TYPE
17.1 OVERVIEW
17.2 UNFRACTIONATED HEPARIN (UFH)
17.2.1 MARKET VALUE (USD MILLION)
17.2.2 MARKET VOLUME
17.2.3 AVERAGE SELLING PRICE (USD)
17.3 LOW MOLECULAR WEIGHT HEPARIN (LMWH)
17.3.1 ENOXAPARIN
17.3.1.1. MARKET VALUE (USD MILLION)
17.3.1.2. MARKET VOLUME
17.3.1.3. AVERAGE SELLING PRICE (USD)
17.3.2 DALTEPARIN
17.3.2.1. MARKET VALUE (USD MILLION)
17.3.2.2. MARKET VOLUME
17.3.2.3. AVERAGE SELLING PRICE (USD)
17.3.3 TINZAPARIN
17.3.3.1. MARKET VALUE (USD MILLION)
17.3.3.2. MARKET VOLUME
17.3.3.3. AVERAGE SELLING PRICE (USD)
17.3.4 FRAXIPARINE
17.3.4.1. MARKET VALUE (USD MILLION)
17.3.4.2. MARKET VOLUME
17.3.4.3. AVERAGE SELLING PRICE (USD)
17.3.5 NADROPARIN
17.3.5.1. MARKET VALUE (USD MILLION)
17.3.5.2. MARKET VOLUME
17.3.5.3. AVERAGE SELLING PRICE (USD)
17.3.6 OTHERS
17.4 ULTRA-LOW MOLECULAR WEIGHT HEPARIN (ULMWH)
17.4.1 SEMULOPARIN
17.4.1.1. MARKET VALUE (USD MILLION)
17.4.1.2. MARKET VOLUME
17.4.1.3. AVERAGE SELLING PRICE (USD)
17.4.2 BEMIPARIN
17.4.2.1. MARKET VALUE (USD MILLION)
17.4.2.2. MARKET VOLUME
17.4.2.3. AVERAGE SELLING PRICE (USD)
17.4.3 OTHERS
18 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY SALT TYPE
18.1 OVERVIEW
18.2 SODIUM
18.3 CALCIUM
18.4 OTHERS
19 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY TYPE
19.1 OVERVIEW
19.2 BRANDED
19.2.1 FRAGMIN
19.2.2 LOVENOX
19.2.3 INNOHEP
19.2.4 LIPO-HEPIN
19.2.5 LIQUAEMIN
19.2.6 PANHEPARIN
19.2.7 HEP-LOCK
19.2.8 HEPALEAN (CALCIPARINE)
19.2.9 OTHERS
19.3 GENERICS
20 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY THERAPEUTICS
20.1 OVERVIEW
20.2 CARDIOVASCULAR
20.2.1 DEEP VEIN THROMBOSIS
20.2.2 PULMONARY EMBOLISM
20.2.3 ARTERIAL THROMBOEMBOLISM
20.2.4 MYOCARDIAL INFARCTION
20.2.5 ATRIAL FIBRILLATION
20.2.6 PERIPHERAL ARTERY DISEASE
20.3 RESPIRATORY
20.3.1 DEEP VEIN THROMBOSIS
20.3.2 PULMONARY EMBOLISM
20.3.3 ARTERIAL THROMBOEMBOLISM
20.3.4 ATRIAL FIBRILLATION
20.3.5 PERIPHERAL ARTERY DISEASE
20.4 ONCOLOGY
20.4.1 DEEP VEIN THROMBOSIS
20.4.2 PULMONARY EMBOLISM
20.4.3 ARTERIAL THROMBOEMBOLISM
20.4.4 ATRIAL FIBRILLATION
20.4.5 PERIPHERAL ARTERY DISEASE
20.5 NEPHROLOGY
20.5.1 DEEP VEIN THROMBOSIS
20.5.2 PULMONARY EMBOLISM
20.5.3 ARTERIAL THROMBOEMBOLISM
20.5.4 ATRIAL FIBRILLATION
20.5.5 PERIPHERAL ARTERY DISEASE
20.6 CNS
20.6.1 DEEP VEIN THROMBOSIS
20.6.2 PULMONARY EMBOLISM
20.6.3 ARTERIAL THROMBOEMBOLISM
20.6.4 ATRIAL FIBRILLATION
20.6.5 PERIPHERAL ARTERY DISEASE
20.7 OTHERS
21 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY MODE OF ADMINISTRATION
21.1 OVERVIEW
21.2 ORAL
21.3 PARENTAL
21.3.1 SUBCUTANEOUS
21.3.2 INTRAVENOUS
21.3.3 INTRAPERITONEAL
21.4 OTHERS
22 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY STRENGTH
22.1 OVERVIEW
22.2 10 UNIT
22.3 100 UNIT
22.4 1000 UNIT
22.5 5000 UNIT
22.6 10,000 UNIT
22.7 25,000 UNIT
22.8 OTHERS
23 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY CONTAINER TYPE
23.1 OVERVIEW
23.2 BOTTLES
23.3 BAGS
23.4 VIALS
23.5 OTHERS
24 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY PACKAGING MATERIAL
24.1 OVERVIEW
24.2 GLASS
24.3 PLASTIC
25 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY APPLICATION
25.1 OVERVIEW
25.2 PRE-SURGICAL PROCEDURES
25.3 POST-SURGICAL PROCEDURES
25.4 KIDNEY DIALYSIS
25.5 DIAGNOSTIC TESTS
25.6 OTHERS
26 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY END USER
26.1 OVERVIEW
26.2 HOSPITALS
26.2.1 PRIVATE
26.2.1.1. TIER 1
26.2.1.2. TIER 2
26.2.1.3. TIER 3
26.2.2 PUBLIC
26.2.2.1. TIER 1
26.2.2.2. TIER 2
26.2.2.3. TIER 3
26.3 SPECIALTY CLINICS
26.4 AMBULATORY SURGICAL CENTERS
26.5 HOME HEALTHCARE
26.6 OTHERS
27 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY DISTRIBUTION CHANNEL
27.1 OVERVIEW
27.2 DIRECT TENDER
27.3 RETAIL SALES
27.3.1 HOSPITAL PHARMACY
27.3.2 RETAIL PHARMACY
27.3.3 ONLINE PHARMACY
27.4 OTHERS
28 MIDDLE EAST AND AFRICA HEPARIN MARKET, SWOT AND DBMR ANALYSIS
29 MIDDLE EAST AND AFRICA HEPARIN MARKET, COMPANY LANDSCAPE
29.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
29.2 MERGERS & ACQUISITIONS
29.3 NEW PRODUCT DEVELOPMENT & APPROVALS
29.4 EXPANSIONS
29.5 REGULATORY CHANGES
29.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
30 MIDDLE EAST AND AFRICA HEPARIN MARKET, BY REGION
MIDDLE EAST AND AFRICA HEPARIN MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
30.1 MIDDLE EAST AND AFRICA
30.1.1 SOUTH AFRICA
30.1.2 EGYPT
30.1.3 BAHRAIN
30.1.4 KUWAIT
30.1.5 OMAN
30.1.6 QATAR
30.1.7 SAUDI ARABIA
30.1.8 UNITED ARAB EMIRATES
30.1.9 REST OF MEA
30.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
31 MIDDLE EAST AND AFRICA HEPARIN MARKET, COMPANY PROFILE
31.1 SANOFI
31.1.1 COMPANY OVERVIEW
31.1.2 REVENUE ANALYSIS
31.1.3 GEOGRAPHIC PRESENCE
31.1.4 PRODUCT PORTFOLIO
31.1.5 RECENT DEVELOPMENTS
31.2 PFIZER INC.
31.2.1 COMPANY OVERVIEW
31.2.2 REVENUE ANALYSIS
31.2.3 GEOGRAPHIC PRESENCE
31.2.4 PRODUCT PORTFOLIO
31.2.5 RECENT DEVELOPMENTS
31.3 FRESENIUS KABI
31.3.1 COMPANY OVERVIEW
31.3.2 REVENUE ANALYSIS
31.3.3 GEOGRAPHIC PRESENCE
31.3.4 PRODUCT PORTFOLIO
31.3.5 RECENT DEVELOPMENTS
31.4 F. HOFFMANN-LA ROCHE LTD
31.4.1 COMPANY OVERVIEW
31.4.2 REVENUE ANALYSIS
31.4.3 GEOGRAPHIC PRESENCE
31.4.4 PRODUCT PORTFOLIO
31.4.5 RECENT DEVELOPMENTS
31.5 VIATRIS INC.
31.5.1 COMPANY OVERVIEW
31.5.2 REVENUE ANALYSIS
31.5.3 GEOGRAPHIC PRESENCE
31.5.4 PRODUCT PORTFOLIO
31.5.5 RECENT DEVELOPMENTS
31.6 ASPEN GLOBAL INCORPORATED.
31.6.1 COMPANY OVERVIEW
31.6.2 REVENUE ANALYSIS
31.6.3 GEOGRAPHIC PRESENCE
31.6.4 PRODUCT PORTFOLIO
31.6.5 RECENT DEVELOPMENTS
31.7 HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD.
31.7.1 COMPANY OVERVIEW
31.7.2 REVENUE ANALYSIS
31.7.3 GEOGRAPHIC PRESENCE
31.7.4 PRODUCT PORTFOLIO
31.7.5 RECENT DEVELOPMENTS
31.8 EISAI CO., LTD.
31.8.1 COMPANY OVERVIEW
31.8.2 REVENUE ANALYSIS
31.8.3 GEOGRAPHIC PRESENCE
31.8.4 PRODUCT PORTFOLIO
31.8.5 RECENT DEVELOPMENTS
31.9 HIKMA PHARMACEUTICALS PLC
31.9.1 COMPANY OVERVIEW
31.9.2 REVENUE ANALYSIS
31.9.3 GEOGRAPHIC PRESENCE
31.9.4 PRODUCT PORTFOLIO
31.9.5 RECENT DEVELOPMENTS
31.1 LEO PHARMA
31.10.1 COMPANY OVERVIEW
31.10.2 REVENUE ANALYSIS
31.10.3 GEOGRAPHIC PRESENCE
31.10.4 PRODUCT PORTFOLIO
31.10.5 RECENT DEVELOPMENTS
31.11 SHANGHAI FOSUN PHARMACEUTICAL（GROUP）CO., LTD.
31.11.1 COMPANY OVERVIEW
31.11.2 REVENUE ANALYSIS
31.11.3 GEOGRAPHIC PRESENCE
31.11.4 PRODUCT PORTFOLIO
31.11.5 RECENT DEVELOPMENTS
31.12 PHARMACIA AND UPJOHN COMPANY LLC (DISTRIBUTED BY - PFIZER)
31.12.1 COMPANY OVERVIEW
31.12.2 REVENUE ANALYSIS
31.12.3 GEOGRAPHIC PRESENCE
31.12.4 PRODUCT PORTFOLIO
31.12.5 RECENT DEVELOPMENTS
31.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
31.13.1 COMPANY OVERVIEW
31.13.2 REVENUE ANALYSIS
31.13.3 GEOGRAPHIC PRESENCE
31.13.4 PRODUCT PORTFOLIO
31.13.5 RECENT DEVELOPMENTS
31.14 SHENZHEN TECHDOW PHARMACEUTICAL CO., LTD
31.14.1 COMPANY OVERVIEW
31.14.2 REVENUE ANALYSIS
31.14.3 GEOGRAPHIC PRESENCE
31.14.4 PRODUCT PORTFOLIO
31.14.5 RECENT DEVELOPMENTS
32 RELATED REPORTS
33 CONCLUSION
34 QUESTIONNAIRE
35 ABOUT DATA BRIDGE MARKET RESEARCH
